William Blair Has Negative Forecast for TARS Q1 Earnings

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) - Research analysts at William Blair lowered their Q1 2025 earnings per share estimates for Tarsus Pharmaceuticals in a research note issued to investors on Tuesday, February 25th. William Blair analyst L. Hanbury-Brown now expects that the company will post earnings per share of ($0.82) for the quarter, down from their previous estimate of ($0.72). The consensus estimate for Tarsus Pharmaceuticals' current full-year earnings is ($3.17) per share. William Blair also issued estimates for Tarsus Pharmaceuticals' Q1 2025 earnings at ($0.82) EPS, Q2 2025 earnings at ($0.52) EPS, Q3 2025 earnings at ($0.32) EPS, Q3 2025 earnings at ($0.32) EPS, Q4 2025 earnings at ($0.05) EPS, Q4 2025 earnings at ($0.05) EPS, FY2025 earnings at ($1.70) EPS and FY2025 earnings at ($1.70) EPS.

A number of other brokerages have also weighed in on TARS. HC Wainwright reissued a "buy" rating and set a $73.00 price target on shares of Tarsus Pharmaceuticals in a research note on Wednesday, February 26th. The Goldman Sachs Group raised their price target on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a "neutral" rating in a research note on Friday, November 15th. Barclays dropped their price objective on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating for the company in a research note on Wednesday, February 26th. Guggenheim reaffirmed a "buy" rating and issued a $78.00 target price (up from $75.00) on shares of Tarsus Pharmaceuticals in a research report on Monday, February 24th. Finally, Oppenheimer boosted their price target on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an "outperform" rating in a research report on Wednesday, January 22nd. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $61.33.

Remove Ads

Tarsus Pharmaceuticals Trading Up 4.3 %

NASDAQ TARS traded up $1.83 during mid-day trading on Friday, reaching $44.55. 394,769 shares of the stock were exchanged, compared to its average volume of 642,828. The stock has a market capitalization of $1.71 billion, a PE ratio of -11.75 and a beta of 1.01. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42. Tarsus Pharmaceuticals has a 1-year low of $20.08 and a 1-year high of $57.28. The business's fifty day simple moving average is $50.74 and its 200 day simple moving average is $43.48.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last released its earnings results on Tuesday, February 25th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.68) by $0.08. The company had revenue of $66.41 million for the quarter, compared to analyst estimates of $58.80 million. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%.

Institutional Trading of Tarsus Pharmaceuticals

A number of hedge funds have recently made changes to their positions in TARS. Toronto Dominion Bank acquired a new stake in Tarsus Pharmaceuticals during the 4th quarter valued at $105,714,000. GF Fund Management CO. LTD. purchased a new position in Tarsus Pharmaceuticals in the fourth quarter valued at about $44,000. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. acquired a new stake in Tarsus Pharmaceuticals during the 4th quarter valued at approximately $3,278,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Tarsus Pharmaceuticals by 18.7% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 69,826 shares of the company's stock valued at $3,866,000 after purchasing an additional 10,991 shares in the last quarter. Finally, Woodline Partners LP increased its holdings in Tarsus Pharmaceuticals by 52.3% during the 4th quarter. Woodline Partners LP now owns 108,986 shares of the company's stock worth $6,035,000 after purchasing an additional 37,417 shares during the last quarter. Hedge funds and other institutional investors own 90.01% of the company's stock.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.